IMGN(Delisted)
ImmunoGenยทNASDAQ
--
--(--)
Is IMGN undervalued or overvalued?
- IMGN scores 0.00/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, -25.56% net margin, 0.00 P/E ratio, 0.00 P/B ratio, and 65.85% earnings growth, these metrics solidify its Neutral investment rating.
